Soliton Inc

Soliton — Investor Presentation (September 2019)

36 slides from Soliton's investor presentation, Sep 19, 2019

  1. Slide 1: Rapid Acoustic Pulse Technology

    soliton Rapid Acoustic Pulse Technology (Nasdaq: SOLY)

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Al statements contained herein other then staternents of historical fact. including statements regarding ou future results of operations and {rancial postion, our business strategy and plans, and cur objectives fr future operations, are forward-looking statements. The words "believe

  3. Slide 3: Overview Summary

    Overview Summary Breakthrough acoustic shockwave device using novel and proprietary Rapid Acoustic Pulse (RAP) technology Induces mechanical éerupton to targeted cellar lvl structures and vacuoles No cavitation het or cotateraltesue damage or pain Platform technology Tattoo removal nas ite es 1/8 th

  4. Slide 4: Brief History

    Brief History Started 2012 with technology from MD Anderson MDAnderson Cancer Center ‘Ganeer Center Founding inventor, from MIT, originated technology Nir that became Dexcom ($11 billion valuation as of 12/31/18) Techno $32 million investment by single Venture Capital Fund pexconr (also participated

  5. Slide 5: Management and Directors

    Management and Directors All life science veterans Multiple device clearances Multiple national and international aesthetic device launches

  6. Slide 6: Science Advisory Board

    Science Advisory Board High profile Key Opinion Leaders Strong podium presence Respected, published searchers Also members of Allergan's CoolSculpting Medical Advisory Board

  7. Slide 7: RAP Device

    RAP Device

  8. Slide 8: Electrode Cartridge

    Electrode Cartridge Electro-hydraulics (arc plasma in saline) utlizes 3000 volts at 3000 amps; creates shockwaves from 2 to 6 MPa @ 100 Hz Electronic wave shaping enables very high repetition rate; reduces unwanted frequencies that cause heat and pain Custom designed reflector eliminates cavitation,

  9. Slide 9: Soliton's Rapid Acoustic Pulse

  10. Slide 10: RAP Therapeutic Effect

    RAP Therapeutic Effect Physical Effects ECM/Fibrous Septa disruption (Acoustic subcision) Non-cavitation/non-thermal physical effects + Biological Effects (from Mechanotransduction) * Collagenesis ‘Angiogenesis | Lymphangiogenesis + Inflammation inhibition

  11. Slide 11: Acoustic ECM Disruption-- Breakthrough

    Acoustic ECM Disruption-- Breakthrough Septa Disruption Time Dose Response Kaye conmel— ee Ona TS, Sey Pits foams Ue nTONO ENE Bio Head: Omega set at higher power 2800y, 100H2, 70ms) ‘Control- 20x 1min-20x 2 min-20x 3 min-20x

  12. Slide 12: Platform Technology

    Platform Technology

  13. Slide 13: Targeted Indications Pathway

    Targeted Indications Pathway

  14. Slide 14: Tattoo Removal: First Indication

    Tattoo Removal: First Indication

  15. Slide 15: Million Americans want some form of tattoo removal

    44 million Americans want some form of tattoo removal 6356" are ‘considering Total US _ ‘Aout Popuiation removal; 28% are *regretters™ Us prospects So, why isn’t this already a billion dollar business? soliton

  16. Slide 16: A complete removal for this patient could mean repeating this visit

    A complete removal for this patient could mean repeating this visit 10 or ~ more times over the next 1 to 2 years (December 2012 Archives of Dermatology) Reducing this timeline will truly change the industry approach soliton

  17. Slide 17: RAP Device Enables Multiple Laser Treatments In One Visit

    RAP Device Enables Multiple Laser Treatments In One Visit more office FDA clearance clinical trials: i a trial par Demonstrated that Soliton’s RAP device erisoed iMate enables multiple laser passes in a single isk of scarring or ghosting Office visit Overall better outcome Achieved tattoo fading res

  18. Slide 18: Statistically Significant Clinical Results

    Statistically Significant Clinical Results Fading After 3 Treatments oy After approximately 3 office * visits, the Soliton RAP in s03% delivered 75% or greater i ea fading in 100% of patients* i ~ Soliton outperformed “laser- i = = 187% only” 100%” of the time ~ Softon « . F LaserOnly “Pes presrtd t

  19. Slide 19: Complete removal of treated ink after treatments

    Complete removal of treated ink after 3 treatments After 8 Treatments

  20. Slide 20: Complete removal of treated ink after treatments

    Complete removal of treated ink after 3 treatments Before After 3 Treatments

  21. Slide 21: Compared with historical controls, Soliton RAP changes the removal timeline

    Compared with historical controls, Soliton RAP changes the removal timeline 8 & — Soiton fang 280%) — Sotton (facing 275%) — Arch Derm Study, Laser-Only 8 Cumulative Success Rate, % 8 a % No. of Treatment Sessions

  22. Slide 22: Cellulite Treatment: Second Indication

    Cellulite Treatment: Second Indication

  23. Slide 23: Cellulite

    Cellulite Cellulite is formed in the subdermal fat layer In this region, fat cells are arranged in chambers ‘surrounded by bands of fiorous septa In certain types of cellulite, the septa can contract and become sclerotic holding portions of the skin with a non-fiexible length of septa This results i

  24. Slide 24: Acoustic subcision device: mechanism of action

    Acoustic subcision device: mechanism of action (ur device emits rapid acoustic shock wave pulses that are transmitted through the skn to breakthe = fibrotic septa = Defects or depressions are lifted by the releasing action of the procedure Direct mechanism is shearing and tearing induced by shock wa

  25. Slide 25: Acoustic subcision device: Procedure

    Acoustic subcision device: Procedure * 20-30 minute procedure can treat much of aleg/buttock area + Non-invasive: Real “incision-less” procedure Skin never punctured + No anesthetic required + Physician oversight of delivery; delegable * No recovery time soliton

  26. Slide 26: Results: Efficacy

    Results: Efficacy Efficacy + 100% correct selection of the before and 12-week post-treatment photos by 49 all binded reviewers + At26 weeks, average reduction of the Cellulite Severity Soale (CSS) to 2.93 a" from 4.27 (p<0.001) Participant Perception of Improvement and = Eatin + 40f5 self reported i

  27. Slide 27: Clinically significant cellulite reduction with RAP

    Clinically significant cellulite reduction with RAP Before 26 Weeks After Single Treatment Before and 26-weeks after a single 20-minute RAP treatment

  28. Slide 28: Subject impression of esthetic improvement

    Subject impression of esthetic improvement ‘Subject Esthetic improvement (week 26) : ce Se : Times 3 F NO CHANGE 2 a os i Pt001 Pt002 PrOO3 PLOO4 PY00S Aye (n=5)

  29. Slide 29: Keloid and Hypertrophic Scar Treatment: Third Indication

    Keloid and Hypertrophic Scar Treatment: Third Indication and Support for Other Fibrotic Disease Targets soliton

  30. Slide 30: RAP Treatment of Fibrosis: Theory

    RAP. Tidatnent of Fibrosis: Theory RAP Treatment for Fibrosis

  31. Slide 31: Our Pipeline in Fibrosis

    Our Pyle in Fibrosis

  32. Slide 32: Revenue Potential

    Revenue Potential Tattoo opportunity: Global market projected to be over S4B by 2023* & e Cellulite opportunity: me |! Global market projected to be | over $1.4B by 2026"* Keloid/Hypertrophic Scar opportunity: Global market projected to be $10B by 2025"

  33. Slide 33: Device and revenue strategy

    Device and revenue strategy | “razor and blade” recurring revenue mode! Replaceable consumable cartridge good for one patient visit Sell or lease Hand piece contains consoles replaceable cartridge

  34. Slide 34: Key Milestones

    Key Milestones Milestone Anticipated Timing FDA Approval for Tattoo Indication A Completed May 2019 Coalluite POC study- 26-week time point | A completed May 2019 Calluite POC 26-week data release in Las Vegas Aesthetics Show A Completed Juy 2019 Pivotal trial for Calle to be inated A. Completed Mid

  35. Slide 35: Capitalization Table

    Capitalization Table {as of August 31, 2019) ‘Common Stock 16,268,545 | Warrants 888,333) $9.53 Options 2,843,550) $2.59 Convertible Debt 136,517) $0.175) TOTAL FDSO 20,136,945|

  36. Slide 36: Thank you

    soliton Rapid Acoustic Pulse Technology (Nasdaq: SOLY) Thank you

Soliton — Investor Presentation (September 2019) on 6ix